• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

    304.00 -6.11 (-1.97%)
    Streaming Delayed Price Updated: 2:44 PM EDT, Apr 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Praxis Precision Medicines, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Proposed Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
    EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
    Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Participate in Upcoming Fireside Chat
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Proposed Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.